Navigation Links
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
Date:3/12/2009

Provides first affordable protease inhibitor for patients in developing countries Complements recent WHO approval earned for the same product

PITTSBURGH, March 12 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.5% controlling interest, has received the first and only tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Lopinavir/Ritonavir Tablets, 200 mg/50 mg. Matrix's version of this product is heat-stable and affordable, making it practical for distribution and use in warm climates.

Mylan Vice Chairman and CEO Robert J. Coury said: "Mylan and Matrix are committed to our growing and high quality antiretroviral franchise. Our goal is to provide HIV treatments to patients around the world -- especially in developing countries. With Matrix's heat-stable and affordable version of Lopinavir/Ritonavir, patients in remote parts of developing nations will have access to this important life-saving drug. This is the second regulatory approval that this important product has recently earned, which further confirms our commitment to providing high-quality medicines at affordable prices."

Lopinavir/Ritonavir Tablets are the generic version of Abbott Laboratories' Kaletra(R) Tablets, the brand marketed in the U.S. and Europe, and Aluvia(R) Tablets, the brand marketed in developing countries. It is used in combination with other medications to control HIV infection and is included in the antiretroviral (ARV) class of drugs known as HIV protease inhibitors.

Last month, Matrix was awarded the first and only World Health Organization (WHO) approval for the same product. These approvals indicate that Matrix's Lopinavir/Ritonavir tablets meet international safety, efficacy and manufacturing quality standards. This status will significantly increase access to affordable, high quality medicines in many countries, particularly priority countries with high AIDS prevalence rates.

Matrix's wide range of ARV products includes active pharmaceutical ingredients (API) and first- and second-line finished doses. Patients often use second-line therapies if and when they develop resistance to initially prescribed treatments or experience clinical failures. The company's emphasis on producing affordable products has allowed it to drive down the average annual cost per patient of effective therapies. Approximately 30% of HIV/AIDS patients in developing countries depend on Matrix ARV products.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CorMatrix Cardiovascular Announces First European Implants of CorMatrix(R) ECM Technology(TM)
2. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
4. Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share
5. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2009 Financial Results
6. Matrixx Initiatives Selects GolinHarris as Agency of Record for Zicam Brand
7. Mylans Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit(R) Capsules
8. BioNanomatrix Appoints Gary Zweiger, Ph.D., as Vice President of Business Development
9. Mylans Matrix First-to-File on Generic Version of Vfend(R) Antifungal
10. Photos: For the First Time Researchers Show Reversal of an Aging Marker in the Human Retina Correlated with Visual Improvement Using a Nutraceutical Matrix (Longevinex(R))
11. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... ... is pleased to welcome new Partner Firm Austin & Co., Inc. Headquartered ... to insurance, employee benefits, HR consulting, benefits technology, and beyond. As an ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... How to ... · Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the ... that human error will ever be totally eliminated, many human performance problems can be ...
(Date:5/24/2016)... — , ... (PRWEB) ... of three new members of its Advisory Board. Joining the ... Sarah Kusch. “All three of them embody the mission of our ... are very fortunate to have them as we continue to expand ...
(Date:5/24/2016)... ... May 24, 2016 , ... Backed by ... logger for each job, ensuring the best suited solution to meet regulatory requirements. ... loggers at their lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s line ...
(Date:5/24/2016)... ... May 24, 2016 , ... The Radiosurgery Society ... of radiosurgery, is recognizing five medical residents and students for their outstanding contributions ... (SBRT). The awards will be presented at the 2016 SRS/SBRT Scientific Meeting taking ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016  Diana Russell suffers from a ... from the inside out.  This disease has put her ... her children and grandchildren to leave her home.  Because ... family cannot haul the wheelchair.  So if there is ... and Diana is left to wait for the bus. ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
(Date:5/24/2016)... , May 24, 2016 ... de doble terapia del mundo, introduce catéteres para ... OrbusNeich, una compañía global especializada en ... vidas, ha expandido su cartera incluyendo productos para ... JADE™ y Scoreflex™ PTA son los dispositivos de ...
Breaking Medicine Technology: